0001140361-24-003036.txt : 20240221 0001140361-24-003036.hdr.sgml : 20240221 20240122122243 ACCESSION NUMBER: 0001140361-24-003036 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ocuphire Pharma, Inc. CENTRAL INDEX KEY: 0001228627 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 113516358 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 37000 GRAND RIVER AVE. STREET 2: SUITE 120 CITY: FARMINGTON HILLS STATE: MI ZIP: 48335 BUSINESS PHONE: 248-681-9815 MAIL ADDRESS: STREET 1: 37000 GRAND RIVER AVE. STREET 2: SUITE 120 CITY: FARMINGTON HILLS STATE: MI ZIP: 48335 FORMER COMPANY: FORMER CONFORMED NAME: REXAHN PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20050516 FORMER COMPANY: FORMER CONFORMED NAME: CORPORATE ROAD SHOW DOT COM INC DATE OF NAME CHANGE: 20030423 CORRESP 1 filename1.htm
January 22, 2024

VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, NE
Washington, D.C. 20549
Attention: Lauren Hamill

 
Re:
Ocuphire Pharma, Inc.
Registration Statement on Form S-3
File No. 333-276462
Acceleration Request

 
Requested Date:
January 23, 2024
 
Requested Time:
4:30 P.M. Eastern Time

Ladies and Gentlemen:
 
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Ocuphire Pharma, Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement on Form S-3 (File No. 333-276462) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon as practicable thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. The Company hereby authorizes each of Emily Johns and Lauren Legner of Honigman LLP, counsel to the Company, to make such request on its behalf.

Please confirm the effectiveness of the Registration Statement with Emily Johns of Honigman LLP by telephone at (616) 649-1908 or Lauren Legner of Honigman LLP by telephone at (313) 465-7119.

[Signature page follows]

****
Sincerely,



Ocuphire Pharma, Inc.



/s/ Amy Rabourn



Amy Rabourn

SVP of Finance

  cc:
Emily Johns, Honigman LLP
Lauren Legner, Honigman LLP